---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic impact of diagnostic testing"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic impact of diagnostic testing. Topics: Misdiagnosis in 59 consecutive patients referred to a US center with a diagnosis of CIDP, Electrodiagnostic interpretation errors in 86 referred patients, Overdiagnosis and immunoglobulin exposure before referral at a Dutch tertiary center, Initial misdiagnosis and diagnostic delay in 1056 patients from eight countries, and 5 further topics. 9 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/economic-impact-of-diagnostic-testing"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic impact of diagnostic testing

<a id="heading-2.2.1.8.4"></a>

## 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

### Misdiagnosis in 59 consecutive patients referred to a US center with a diagnosis of CIDP

> “A retrospective study of 59 consecutive patients referred with a diagnosis of CIDP was performed.”
> “Forty-seven percent of patients referred with a diagnosis of CIDP failed to meet minimal CIDP diagnostic requirements.”
> “Patients frequently reported improvements after being treated with immunotherapy, even if the CIDP diagnosis was incorrect.”
> “Over-reliance on subjective patient-reported perception of treatment benefit, liberal electrophysiologic interpretation of demyelination, and placing an overstated importance on mild or moderate cytoalbuminologic dissociation are common diagnostic errors.”

Source: [Allen and Lewis (2015)](https://pubmed.ncbi.nlm.nih.gov/26180143/)

<a id="topic-2.2.1.8.4-2"></a>

### Electrodiagnostic interpretation errors in 86 referred patients

> “Thirty-nine of 86 patients were found not to have CIDP. Initial electrodiagnostic data quality was generally acceptable, but initial electrodiagnostic conclusions were confirmed in only 45% of misdiagnosed studies.”

Source: [Allen et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29053880/)

<a id="topic-2.2.1.8.4-3"></a>

### Overdiagnosis and immunoglobulin exposure before referral at a Dutch tertiary center

> “A referral diagnosis of CIDP was revised in 32% of patients (31/96; overdiagnosis).”
> “In the overdiagnosed patients, 20% of muscle weakness was asymmetric, 48% lacked proximal muscle weakness, 29% only had distal muscle weakness, 65% did not fulfil the electrodiagnostic criteria for CIDP, 74% had an elevated cerebrospinal fluid (CSF) protein level, and 97% had another type of neuropathy.”
> “Treatment Before referral, 52% of overdiagnosed patients ( n = 16) were treated for CIDP with intravenous immunoglobulins (IVIg; n = 12), corticosteroids ( n = 1), or IVIg and corticosteroids ( n = 3).”

Source: [Broers et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8252611/)

<a id="topic-2.2.1.8.4-4"></a>

### Initial misdiagnosis and diagnostic delay in 1056 patients from eight countries

> “Overall, initial misdiagnosis occurred in 37.2% of patients, with a median (interquartile range) diagnostic delay of 6.0 (3.0–12.0) months.”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

<a id="topic-2.2.1.8.4-5"></a>

### Electrodiagnostic testing before immunoglobulin initiation in 3975 US claims patients

> “Of 32,090 patients with CIDP identified, 3975 (mean age 57 years) subsequently initiated IVIG.”
> “CIDP-related laboratory/diagnostic procedures were performed in approximately 20– > 40% of patients in the 3 months prior to IVIG initiation (63.7% underwent electrodiagnostic/nerve conduction testing in the 6 months prior to IVIG initiation).”
> “In addition, some patients received IVIG therapy in the absence of electrodiagnostic or nerve conduction tests.”

Source: [Layton et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10310640/)

<a id="topic-2.2.1.8.4-6"></a>

### Electrophysiological findings as a US payer requirement for immunoglobulin coverage

> “Several US payers mandate positive electrophysiological findings on at least three of four tests (per guidelines from the American Academy of Neurology [AAN]) as part of medical necessity for CIDP treatment, particularly intravenous immunoglobulin (IVIg)”

Source: [Divino et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6198979/)

<a id="topic-2.2.1.8.4-7"></a>

### Treatment cost in Charcot-Marie-Tooth disease misdiagnosed as CIDP compared with the cost of genetic testing

> “Among 1104 CIDP cases, we identified 35 CMT patients misdiagnosed as CIDP (3.2%).”
> “Treatment cost in these 35 misdiagnosed patients was estimated at 4.6 million euros (M€), whereas the cost of CMT genetic analysis in 1104 patients was estimated at 2.7 M€.”
> “Importantly, the cost of treating these 35 misdiagnosed patients was significantly higher than the cost of performing CMT genetic analysis in 1104 patients (4.6 M€ vs. 2.7 M€), suggesting that CMT genetic investigations should be more widely used before diagnosing CIDP.”

Source: [Hauw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34060689/)

<a id="topic-2.2.1.8.4-8"></a>

### Costs of POEMS syndrome misdiagnosed as CIDP and cost-effectiveness of VEGF testing

> “Delay in diagnosis is common with 55% of patients initially incorrectly diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).”
> “Treatment associated with an incorrect CIDP diagnosis led to total wasted healthcare expenditures of between £808 550 and £1 111 756 across our cohort, with an average cost-per-POEMS-patient misdiagnosed of £14 701 to £20 214.”
> “Introducing mandatory VEGF testing for patients with acquired demyelinating neuropathy would lead to annual cost-savings of £107 398 for the National Health Service and could prevent misdiagnosis in 16 cases per annum.”

Source: [Marsh et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33106368/)

<a id="topic-2.2.1.8.4-9"></a>

### Electrodiagnostic confirmation as a condition of reimbursement for efgartigimod in Canada

> “Vyvgart SC should only be covered for adults with CIDP confirmed by electrodiagnostic testing, or for adults with possible CIDP based on clinical features and at least 2 supportive criteria consistent with current guidelines.”

Source: [CDA-AMC efgartigimod alfa reimbursement recommendation (2026)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/SR0894/2990?inline=1)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
